COA-2026-SC-00015
Issued · May 26, 2026
Toronto, ON, Canada

Certificate *of* Analysis

Retatrutide
Sample ID: RET-006

IDENTITY	TOTAL SAMPLE MASS	PURITY · HPLC
CONFIRMED	72.0 mg	98.8 %

§ 01 Sample & Submission

FOR RESEARCH PURPOSES ONLY

ANALYTE

PRODUCT Retatrutide
CAS 2381089-83-2
SAMPLE ID RET-006
SAMPLE FORM Lyophilized powder
RECEIVED May 22, 2026
REPORTED May 26, 2026
TOTAL SAMPLE MASS 72.0 mg
EXPECTED ACTIVE INGREDIENT 10.000 mg
LOT NUMBER —

Total sample mass is the gravimetric weight of the entire sample as received in the lab (peptide plus any matrix, counter-ions, or excipients). **Expected active ingredient** is the peptide amount declared on the sample container — the reference value used in the purity calculation.

DISTRIBUTOR

NAME Peptide Test Canada
CONTACT PTC Operations
EMAIL Info@peptidetestcanada.ca
ADDRESS Canada

END CUSTOMER

NAME Viva Peptides
EMAIL info@vivapeptides.ca
ADDRESS Canada

§ 02 Purity · LC-MS/MS (MRM)

METHOD B · AGILENT 6470 · ESI+ · TRIPLE QUAD

PEPTIDE	FORMULA	EXACT MASS (MONO.)	PRECURSOR [M+5H]5+	Quantifier transition ● MRM
Retatrutide	C229H366N50O75	4734.40 Da	947.90 Da	947.90 › 136.10 CE 30 V



ROLE	TRANSITION	CE
Quantifier	947.9 › 136.1	30 V
Qualifier	947.9 › 110.1	35 V

TOTAL SAMPLE MASS	EXPECTED ACTIVE INGREDIENT	LC-MS ACTIVE PEPTIDE	PURITY
72.0 mg	10.000 mg	9.675 mg	98.75 %

Total sample mass is the gravimetric weight of the entire sample as received in the lab. **Expected active ingredient** is the peptide amount declared on the sample label. **LC-MS active peptide** is the actual peptide mass identified by MRM.

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 µm · Solvent A: 0.1 % formic acid in H_2O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY
This report documents **analytical results only**. Provided for **research purposes only**; not a drug-release or quality certification. SideChain Analytics makes no representation regarding resale, clinical use, or human / veterinary administration of the material.

CERTIFICATE OF ANALYSIS

Endotoxin Test

Report No.:	QC-2026-025	**Testing Lab:**	Peptide Test Canada
Lot Number:	Retatrutide/Viva	**Method (Endo):**	USP <85> Kinetic Turbidimetric
Test Date:	May 20, 2026	**Status:**	ALL TESTS PASSED ✓
Report Date:	May 25, 2026		

1. Retatrutide

Lot Number: Retatrutide/Viva **Appearance:** White lyophilized powder

Bacterial Endotoxin Testing (USP <85> — LAL Kinetic Turbidimetric)

Test / Organism	Acceptance Criteria	Result	Status
Bacterial Endotoxins (LAL)	< 1.0 EU/mg	< 0.10 EU/mg	**PASS**
Endotoxin Spike Recovery	50 – 200 %	98.8 %	**PASS**
Reagent Blank	< 0.005 EU/mL	< 0.005 EU/mL	**PASS**

✔ENDOTOXIN TESTS PASSED — COMPLIANT WITH HEALTH CANADA SPECIFICATIONS

CERTIFICATE OF ANALYSIS

Heavy Metal Testing Report

Peptide Test Canada | ISO/IEC 17025:2017 Accredited |

Report Number:	HM-2026-0414-001
Report Date:	May 25, 2026
Test Date:	May 22, 2026
Lot Number:	RETATRUTIDE / Viva
Testing Method:	ICP-MS (Inductively Coupled Plasma – Mass Spectrometry)
Method Reference:	USP <232> / ICH Q3D; EPA Method 6020B
Instrument:	Agilent 7900 ICP-MS
Analyst:	Dr. M. Salem, Ph.D.
Laboratory:	Peptide Test Canada | 16 Falconer Drive, Suite 14 | Mississauga, ON L5N 3M1 | Canada | +1 (416) 800-8008

Retatrutide— Peptide

Compound: Retatrutide	**Lot #:** Retatrutide/Viva	**Test Date:** May 22, 2026	**Overall Result:**	**PASS**

Metal / Element	Symbol	Result	Limit	Unit	Status
Arsenic (As)	As	<0.008	<2.0	µg/g	**PASS**
Cadmium (Cd)	Cd	<0.002	<0.5	µg/g	**PASS**
Lead (Pb)	Pb	<0.003	<0.5	µg/g	**PASS**
Mercury (Hg)	Hg	<0.009	<0.3	µg/g	**PASS**
Antimony (Sb)	Sb	<0.002	<1200	µg/g	**PASS**
Barium (Ba)	Ba	<0.010	<1400	µg/g	**PASS**
Chromium (Cr)	Cr	<0.01	<250	µg/g	**PASS**
Copper (Cu)	Cu	<0.020	<300	µg/g	**PASS**
Molybdenum (Mo)	Mo	<0.010	<300	µg/g	**PASS**
Nickel (Ni)	Ni	<0.03	<200	µg/g	**PASS**
Tin (Sn)	Sn	<0.010	<600	µg/g	**PASS**
Vanadium (V)	V	<0.06	<100	µg/g	**PASS**

All analytes measured by ICP-MS (Inductively Coupled Plasma – Mass Spectrometry) against certified reference standards. Results are reported on an as-received basis. Limits conform to USP <232> / ICH Q3D elemental impurity guidelines for parenteral/oral pharmaceutical products.